At the 16th annual Transcatheter Cardiovascular Therapeutics (TCT) meeting in Washington in late September, companies big and small presented compelling data from various studies for new products that they hope will lead to newly approved products in the interventional cardiology sector as well as showcased recently cleared devices that could potentially revolutionize the medical field.